S. L. Mouhaër

Abstract S6-01:PIK3CAstatus in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial:

J. Baselga, H. Iwata, W. Jonat, 2016 .

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

S. Chan, A. Urruticoechea, T. Pluard, 2018, Breast Cancer Research and Treatment.

Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity : relationship with gut microbiome richness and ecology [plus Supplementary data]

Jean-Michel Batto, F. Levenez, N. Pons, 2016 .